title: Efficacy and safety of subconjunctival bevacizumab for recurrent pterygium.
abstract: OBJECTIVE
  To evaluate the clinical outcome(s) and complication(s) of subconjunctival bevacizumab treatment in patients with recurrent pterygium.
  
  
  METHODS
  This prospective case series included patients who had undergone pterygium surgery and were diagnosed with recurrent pterygium. All patients received one subconjunctival injection of 0.5 mL of bevacizumab (2.5 mg/0.1 mL). The main outcome was the change in size and clinical appearance. The clinical appearance of the pterygium was graded according to Tan and colleagues. The horizontal size of the pterygium (from limbus to apex) was recorded from baseline to 2 months after injection. Treatment-related complications and adverse events were reported.
  
  
  RESULTS
  We included 36 eyes of 36 patients (18 males) with a mean age of 58.75 ± 10.98 years. Totally, 30.6% patients developed recurrent pterygium in both eyes (only the worst eye was treated), with 47.2% developing it in the left eye and 22.2% in the right eye. More than half the patients (58.3%) had a family history of pterygium. There was a significant difference in the size of pterygium at different intervals (P<0.05). Approximately two-thirds (66.7%) of patients presented with hyposphagma on the 2nd day after subconjunctival application; this value decreased to 30.6% by day 7 and to 0% at 1 month. Most patients (69.4%) exhibited amelioration of irritative symptoms within 2 days, 88.9% after 7 days, and 97.2% after 1 month.
  
  
  CONCLUSIONS
  Subconjunctival bevacizumab injection is useful for the management of patients with recurrent pterygium, with no significant local or systemic adverse effects.
authors: Goiânia Eye Institute, Goiânia, Goiás, Brazil.
authors: Larissa Rossana Souza
authors: LR
authors: Stival
authors: Goiânia Eye Institute, Goiânia, Goiás, Brazil.
authors: Anelise Medeiros
authors: AM
authors: Lago
authors: Goiânia Eye Institute, Goiânia, Goiás, Brazil.
authors: Marisa Novaes Falleiro Chaves de
authors: MN
authors: Figueiredo
authors: Goiânia Eye Institute, Goiânia, Goiás, Brazil.
authors: Ricardo Henrique Goulart
authors: RH
authors: Bittar
authors: Goiânia Eye Institute, Goiânia, Goiás, Brazil.
authors: Márcia Leite
authors: ML
authors: Machado
authors: Goiânia Eye Institute, Goiânia, Goiás, Brazil.
authors: João Jorge
authors: JJ
authors: Nassaralla Junior
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy* / Q000601:surgery; D012008:Recurrence; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab